Symbols / AURA Stock $7.01 -0.57% Aura Biosciences, Inc.

Healthcare • Biotechnology • United States • NGM
AURA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Elisabet de los Pinos Ph.D.
Exch · Country NGM · United States
Market Cap 450.04M
Enterprise Value 322.83M
Income -106.19M
Sales —
FCF (ttm) -48.09M
Book/sh 2.15
Cash/sh 2.25
Employees 113
Insider 10d —
IPO Oct 29, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -3.45
PEG —
P/S —
P/B 3.26
P/C —
EV/EBITDA -2.89
EV/Sales —
Quick Ratio 7.85
Current Ratio 8.15
Debt/Eq 12.69
LT Debt/Eq —
EPS (ttm) -1.76
EPS next Y -2.03
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-14
Earnings (prior) 2026-03-30
ROA -40.06%
ROE -73.52%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 64.20M
Shs Float 37.13M
Insider Own 1.63%
Instit Own 84.47%
Short Float 4.28%
Short Ratio 6.43
Short Interest 2.01M
52W High 7.68
vs 52W High -8.72%
52W Low 4.34
vs 52W Low 61.33%
Beta 0.35
Impl. Vol. 13.56%
Rel Volume 0.73
Avg Volume 269.33K
Volume 197.07K
Target (mean) $20.40
Tgt Median $22.00
Tgt Low $15.00
Tgt High $26.00
# Analysts 5
Recom None
Prev Close $7.05
Price $7.01
Change -0.57%
About

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$20.40
Mean price target
2. Current target
$7.01
Latest analyst target
3. DCF / Fair value
$-13.48
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$7.01
Low
$15.00
High
$26.00
Mean
$20.40

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-29 main HC Wainwright & Co. Buy → Buy $24
2026-03-30 reit HC Wainwright & Co. Buy → Buy $22
2025-08-13 reit HC Wainwright & Co. Buy → Buy $22
2025-05-23 reit JMP Securities Market Outperform → Market Outperform $19
2025-03-26 main JMP Securities Market Outperform → Market Outperform $19
2025-03-26 main Citizens Capital Markets Market Outperform → Market Outperform $19
2025-03-25 main HC Wainwright & Co. Buy → Buy $25
2025-03-24 reit HC Wainwright & Co. Buy → Buy $22
2024-12-05 main JMP Securities Market Outperform → Market Outperform $21
2024-11-14 reit HC Wainwright & Co. Buy → Buy $22
2024-10-18 main Scotiabank Sector Outperform → Sector Outperform $23
2024-10-18 main BTIG Buy → Buy $24
2024-10-18 main HC Wainwright & Co. Buy → Buy $22
2024-09-13 main JMP Securities Market Outperform → Market Outperform $23
2024-09-13 reit HC Wainwright & Co. Buy → Buy $21
2024-08-28 reit JMP Securities Market Outperform → Market Outperform $19
2024-07-25 init HC Wainwright & Co. — → Buy $21
2023-12-08 main BTIG Buy → Buy $21
2023-11-10 main JMP Securities Market Outperform → Market Outperform $19
2023-07-27 init Scotiabank — → Sector Outperform $23
News
RSS: Latest AURA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-16 KILROY CONOR Officer — 11,738 $7.02 $82,401
2026-03-02 GIBNEY ANTHONY S. Chief Financial Officer — 71,245 $0.00 $0
2026-03-02 KILROY CONOR Officer — 62,339 $0.00 $0
2026-03-02 PLAVSIC MARK Chief Technology Officer — 62,339 $0.00 $0
2026-03-02 ELISABET DE LOS PINOS Chief Executive Officer — 166,000 $0.00 $0
2026-03-02 HOPKINS JANET JILL Officer — 89,056 $0.00 $0
2026-03-02 ELAZZOUZI AMY F Officer — 44,528 $0.00 $0
2026-02-17 KILROY CONOR Officer — 12,079 $5.05 $60,999
2026-02-17 PLAVSIC MARK Chief Technology Officer — 15,890 $5.05 $80,244
2026-02-17 ELISABET DE LOS PINOS Chief Executive Officer — 47,648 $5.06 $241,099
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
112.79
+17.35%
96.12
+13.09%
84.99
+40.96%
60.30
Research And Development
90.30
+23.19%
73.30
+12.37%
65.23
+54.44%
42.24
Selling General And Administration
22.49
-1.42%
22.81
+15.46%
19.76
+9.43%
18.06
General And Administrative Expense
22.49
-1.42%
22.81
+15.46%
19.76
+9.43%
18.06
Other Gand A
22.49
-1.42%
22.81
+15.46%
19.76
+9.43%
18.06
Total Expenses
112.79
+17.35%
96.12
+13.09%
84.99
+40.96%
60.30
Operating Income
-112.79
-17.35%
-96.12
-13.09%
-84.99
-40.96%
-60.30
Total Operating Income As Reported
-112.79
-17.35%
-96.12
-13.09%
-84.99
-40.96%
-60.30
EBITDA
-111.66
-17.67%
-94.89
-13.38%
-83.70
-41.57%
-59.12
Normalized EBITDA
-111.66
-17.67%
-94.89
-13.10%
-83.90
-42.69%
-58.80
Reconciled Depreciation
1.13
-7.69%
1.22
-5.56%
1.29
+10.03%
1.18
EBIT
-112.79
-17.35%
-96.12
-13.09%
-84.99
-40.96%
-60.30
Total Unusual Items
—
0.00
-100.00%
0.21
+165.41%
-0.32
Total Unusual Items Excluding Goodwill
—
0.00
-100.00%
0.21
+165.41%
-0.32
Special Income Charges
—
0.00
-100.00%
0.21
+165.41%
-0.32
Net Income
-106.19
-22.17%
-86.92
-13.76%
-76.41
-30.03%
-58.76
Pretax Income
-106.08
-22.21%
-86.81
-13.81%
-76.27
-29.79%
-58.76
Net Non Operating Interest Income Expense
6.63
-29.67%
9.43
+9.79%
8.59
+360.73%
1.86
Net Interest Income
6.63
-29.67%
9.43
+9.79%
8.59
+360.73%
1.86
Interest Income Non Operating
6.63
-29.67%
9.43
+9.79%
8.59
+360.73%
1.86
Interest Income
6.63
-29.67%
9.43
+9.79%
8.59
+360.73%
1.86
Other Income Expense
0.08
+164.17%
-0.12
-190.91%
0.13
+139.76%
-0.33
Other Non Operating Income Expenses
0.08
+164.17%
-0.12
-57.89%
-0.08
-442.86%
-0.01
Gain On Sale Of Security
—
—
—
-0.01
Tax Provision
0.11
-3.57%
0.11
-18.25%
0.14
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-106.19
-22.17%
-86.92
-13.76%
-76.41
-30.03%
-58.76
Net Income From Continuing Operation Net Minority Interest
-106.19
-22.17%
-86.92
-13.76%
-76.41
-30.03%
-58.76
Net Income From Continuing And Discontinued Operation
-106.19
-22.17%
-86.92
-13.76%
-76.41
-30.03%
-58.76
Net Income Continuous Operations
-106.19
-22.17%
-86.92
-13.76%
-76.41
-30.03%
-58.76
Normalized Income
-106.19
-22.17%
-86.92
-13.45%
-76.62
-31.09%
-58.45
Net Income Common Stockholders
-106.19
-22.17%
-86.92
-13.76%
-76.41
-30.03%
-58.76
Diluted EPS
-1.76
-0.57%
-1.75
+9.33%
-1.93
+1.53%
-1.96
Basic EPS
-1.76
-0.57%
-1.75
+9.33%
-1.93
+1.53%
-1.96
Basic Average Shares
60.34
+21.52%
49.65
+25.32%
39.62
+32.34%
29.94
Diluted Average Shares
60.34
+21.52%
49.65
+25.32%
39.62
+32.34%
29.94
Diluted NI Availto Com Stockholders
-106.19
-22.17%
-86.92
-13.76%
-76.41
-30.03%
-58.76
Gain On Sale Of PPE
—
0.00
-100.00%
0.21
+165.41%
-0.32
Preferred Stock Dividends
—
—
—
—
Total Other Finance Cost
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
169.43
-7.16%
182.50
-28.45%
255.07
+13.91%
223.94
Current Assets
149.74
-6.78%
160.62
-30.70%
231.79
+17.84%
196.70
Cash Cash Equivalents And Short Term Investments
144.24
-4.54%
151.09
-33.19%
226.15
+19.78%
188.81
Cash And Cash Equivalents
59.52
+87.79%
31.69
-22.82%
41.06
-66.23%
121.58
Other Short Term Investments
84.73
-29.04%
119.40
-35.49%
185.09
+175.31%
67.23
Prepaid Assets
4.32
-43.88%
7.70
+139.52%
3.22
-55.06%
7.16
Restricted Cash
—
0.00
-100.00%
0.02
-5.00%
0.02
Other Current Assets
1.18
-35.65%
1.83
-24.20%
2.41
+236.92%
0.71
Total Non Current Assets
19.69
-10.00%
21.88
-6.02%
23.28
-14.51%
27.23
Net PPE
18.45
-10.40%
20.59
-6.41%
22.00
-15.51%
26.04
Gross PPE
25.50
-4.05%
26.58
-1.70%
27.04
-9.58%
29.91
Accumulated Depreciation
-7.05
-17.81%
-5.99
-18.86%
-5.04
-30.33%
-3.86
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
—
—
0.29
+117.29%
0.13
Construction In Progress
0.23
-16.18%
0.27
-30.43%
0.39
-78.34%
1.80
Other Properties
24.80
-3.99%
25.84
-3.05%
26.65
-5.17%
28.10
Leases
0.47
+0.00%
0.47
0.00
0.00
Other Non Current Assets
1.24
-3.65%
1.29
+0.70%
1.28
+7.22%
1.19
Total Liabilities Net Minority Interest
32.52
+6.50%
30.53
+4.47%
29.23
+3.09%
28.35
Current Liabilities
18.38
+23.27%
14.91
+20.68%
12.36
+18.17%
10.46
Payables And Accrued Expenses
8.89
+45.31%
6.12
+16.97%
5.23
+17.20%
4.46
Payables
1.55
-32.77%
2.30
+28.93%
1.79
-38.82%
2.92
Accounts Payable
1.55
-32.77%
2.30
+28.93%
1.79
-38.82%
2.92
Current Accrued Expenses
7.34
+92.45%
3.82
+10.77%
3.44
+123.27%
1.54
Pensionand Other Post Retirement Benefit Plans Current
6.00
+10.06%
5.46
+55.75%
3.50
+29.50%
2.71
Current Debt And Capital Lease Obligation
3.24
+2.99%
3.15
+17.19%
2.69
-9.31%
2.96
Current Capital Lease Obligation
3.24
+2.99%
3.15
+17.19%
2.69
-9.31%
2.96
Other Current Liabilities
0.24
+28.72%
0.19
-79.89%
0.94
+187.69%
0.33
Total Non Current Liabilities Net Minority Interest
14.13
-9.51%
15.62
-7.41%
16.87
-5.73%
17.89
Long Term Debt And Capital Lease Obligation
14.13
-9.51%
15.62
-7.41%
16.87
-5.73%
17.89
Long Term Capital Lease Obligation
14.13
-9.51%
15.62
-7.41%
16.87
-5.73%
17.89
Non Current Deferred Liabilities
—
—
—
—
Stockholders Equity
136.91
-9.91%
151.97
-32.71%
225.85
+15.47%
195.58
Common Stock Equity
136.91
-9.91%
151.97
-32.71%
225.85
+15.47%
195.58
Capital Stock
0.00
0.00
0.00
0.00
Common Stock
0.00
0.00
0.00
0.00
Preferred Stock
—
—
—
—
Share Issued
63.59
+27.18%
50.00
+1.31%
49.35
+30.65%
37.77
Ordinary Shares Number
63.59
+27.18%
50.00
+1.31%
49.35
+30.65%
37.77
Additional Paid In Capital
617.43
+17.40%
525.93
+2.60%
512.62
+26.09%
406.56
Retained Earnings
-480.42
-28.38%
-374.23
-30.25%
-287.31
-36.23%
-210.90
Gains Losses Not Affecting Retained Earnings
-0.10
-138.78%
0.26
-51.21%
0.54
+848.61%
-0.07
Other Equity Adjustments
-0.10
-138.78%
0.26
-51.21%
0.54
+848.61%
-0.07
Total Equity Gross Minority Interest
136.91
-9.91%
151.97
-32.71%
225.85
+15.47%
195.58
Total Capitalization
136.91
-9.91%
151.97
-32.71%
225.85
+15.47%
195.58
Working Capital
131.36
-9.85%
145.71
-33.60%
219.44
+17.82%
186.25
Invested Capital
136.91
-9.91%
151.97
-32.71%
225.85
+15.47%
195.58
Total Debt
17.38
-7.42%
18.77
-4.03%
19.56
-6.24%
20.86
Capital Lease Obligations
17.38
-7.42%
18.77
-4.03%
19.56
-6.24%
20.86
Net Tangible Assets
136.91
-9.91%
151.97
-32.71%
225.85
+15.47%
195.58
Tangible Book Value
136.91
-9.91%
151.97
-32.71%
225.85
+15.47%
195.58
Derivative Product Liabilities
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-84.74
-6.19%
-79.81
-24.99%
-63.85
-16.93%
-54.60
Cash Flow From Continuing Operating Activities
-84.74
-6.19%
-79.81
-24.99%
-63.85
-16.93%
-54.60
Net Income From Continuing Operations
-106.19
-22.17%
-86.92
-13.76%
-76.41
-30.03%
-58.76
Depreciation Amortization Depletion
1.13
-7.69%
1.22
-5.56%
1.29
+10.03%
1.18
Depreciation
1.13
-7.69%
1.22
-5.56%
1.29
+10.03%
1.18
Depreciation And Amortization
1.13
-7.69%
1.22
-5.56%
1.29
+10.03%
1.18
Other Non Cash Items
1.58
+7.35%
1.47
-19.98%
1.84
+89.77%
0.97
Stock Based Compensation
14.32
+22.14%
11.72
+33.63%
8.77
+36.81%
6.41
Operating Gains Losses
—
—
0.21
+1045.45%
-0.02
Gain Loss On Investment Securities
—
—
—
—
Gain Loss On Sale Of PPE
—
0.00
-100.00%
0.21
+1045.45%
-0.02
Change In Working Capital
5.97
+326.00%
-2.64
-159.49%
4.44
+215.47%
-3.85
Change In Prepaid Assets
4.03
+203.25%
-3.90
-209.08%
3.58
+210.02%
-3.25
Change In Payables And Accrued Expense
3.29
+59.54%
2.06
-9.30%
2.27
+295.47%
0.57
Change In Accrued Expense
4.13
+161.95%
1.58
-52.36%
3.31
+1314.53%
0.23
Change In Payable
-0.85
-275.52%
0.48
+146.35%
-1.04
-405.88%
0.34
Change In Account Payable
-0.85
-275.52%
0.48
+146.35%
-1.04
-405.88%
0.34
Change In Other Current Assets
0.05
+622.22%
-0.01
+89.53%
-0.09
+79.67%
-0.42
Change In Other Current Liabilities
-1.39
-76.65%
-0.79
+40.39%
-1.32
-77.69%
-0.74
Investing Cash Flow
35.59
-48.28%
68.82
+160.39%
-113.96
-67.92%
-67.87
Cash Flow From Continuing Investing Activities
35.59
-48.28%
68.82
+160.39%
-113.96
-67.92%
-67.87
Net PPE Purchase And Sale
-0.45
+64.33%
-1.25
-76.73%
-0.71
+35.19%
-1.09
Purchase Of PPE
-0.45
+64.33%
-1.25
-76.73%
-0.71
+35.19%
-1.09
Capital Expenditure
-0.45
+64.33%
-1.25
-76.73%
-0.71
+35.19%
-1.09
Net Investment Purchase And Sale
36.04
-48.57%
70.07
+161.87%
-113.25
-69.61%
-66.78
Purchase Of Investment
-83.96
-42.04%
-59.11
+74.70%
-233.65
-95.06%
-119.78
Sale Of Investment
120.00
-7.11%
129.18
+7.30%
120.40
+127.13%
53.01
Financing Cash Flow
77.16
+4737.30%
1.59
-98.36%
97.29
+1.74%
95.63
Cash Flow From Continuing Financing Activities
77.16
+4737.30%
1.59
-98.36%
97.29
+1.74%
95.63
Net Common Stock Issuance
52.57
0.00
-100.00%
95.79
+1020.44%
8.55
Proceeds From Stock Option Exercised
24.58
+1441.32%
1.59
+6.05%
1.50
+249.77%
0.43
Net Other Financing Charges
—
—
—
—
Changes In Cash
28.01
+398.31%
-9.39
+88.34%
-80.52
-199.99%
-26.84
Effect Of Exchange Rate Changes
-0.19
0.00
—
—
Beginning Cash Position
32.46
-22.43%
41.85
-65.80%
122.37
-17.99%
149.21
End Cash Position
60.28
+85.71%
32.46
-22.43%
41.85
-65.80%
122.37
Free Cash Flow
-85.19
-5.10%
-81.06
-25.56%
-64.56
-15.91%
-55.70
Amortization Of Securities
-1.55
+66.82%
-4.66
-16.71%
-3.99
-657.50%
-0.53
Common Stock Issuance
52.57
0.00
-100.00%
95.79
+1020.44%
8.55
Issuance Of Capital Stock
52.57
0.00
-100.00%
95.79
+0.62%
95.20
Net Preferred Stock Issuance
—
—
92.62
+6.89%
86.65
Preferred Stock Issuance
—
—
92.62
+6.89%
86.65
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category